Use of Step Through Policies for Competitive Biologics Among Commercial US Insurers

  • This page as PDF


Avalere evaluated payer policies for biologics when biosimilars are available.

Biosimilar product uptake has been relatively slow in the United States (US) as compared to other markets in developed countries. To understand coverage decisions and formulary design for biologics when biosimilars are available, Avalere assessed coverage and formulary design for the top 25 payers in the US (about 189M covered lives) using publicly available coverage policies.

Key findings of our review include:

  • 78% of plans (representing 81% of covered lives) with publicly available medical coverage information require patients to step through one version of a DMARD (which may be a biologic or generic) before the subsequent treatment; and
  • 56% of plans (representing 76% of covered lives) with publicly available formulary information use tiering to designate preference for one version of pharmacy biologics or biosimilars over the competitor.

Read the full report.

To receive more expert insights on the latest healthcare news, connect with us.

Webinar | Election 2024: What’s at Stake for Healthcare? 

On August 14 at 1:30 PM ET, Avalere experts and guests will discuss the 2024 elections, exploring the candidates’ health policy approaches and implications for stakeholders. 

Learn More

From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Regulatory Strategy and FDA Policy
Please enter your email address to be notified when new Regulatory Strategy and FDA Policy insights are published.

Back To Top